7 assets in Uterine Carcinosarcoma

Therapeutic assets addressing Uterine Carcinosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dostarlimab Uterine Carcinosarcoma	ARCAGY/ GINECO GROUP	P2/3	B (57)
Niraparib Uterine Carcinosarcoma	ARCAGY/ GINECO GROUP	P2/3	B (57)
Tislelizumab Uterine Carcinosarcoma	SOLTI Breast Cancer Research Group	P2	CCC (53)
Pasifolate Exatecan Uterine Carcinosarcoma	Elucida Oncology	P1/2	CCC (48)
Vls-1488 Uterine Carcinosarcoma	Volastra Therapeutics, Inc.	P1/2	CCC (48)
Spartalizumab Uterine Carcinosarcoma	SOLTI Breast Cancer Research Group	P2	CC (46)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tnfrsf4 (Tumor Necrosis Factor Receptor (Tnfr) Superfamily Member 4, Ox40, Cd134)], Homo Sapiens Monoclonal Antibody Uterine Carcinosarcoma	HiFiBiO Therapeutics	P1	CC (43)